BRISTOL-MYERS SQUIBB COMPANY Impairment of Intangible Assets, Finite-lived
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2022-02-09
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, finite-lived for the quarter ending 2021-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, finite-lived for the quarter ending 2021-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, finite-lived for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, finite-lived for the quarter ending 2021-03-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, finite-lived for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, finite-lived for fiscal 2020 was $21.00M, a 40.00% increase from fiscal 2019.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, finite-lived for fiscal 2019 was $15.00M, a 76.56% decline from fiscal 2018.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, finite-lived for fiscal 2018 was $64.00M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $0.00 derived: sum of 2 quarters · filed 2022-02-09 | $0.00 derived: sum of 3 quarters · filed 2022-02-09 | $0.00 10-K · filed 2022-02-09 |
| 2021-09-30 | $0.00 10-Q · filed 2021-10-27 | $0.00 derived: sum of 2 quarters · filed 2021-10-27 | $0.00 10-Q · filed 2021-10-27 | $0.00 derived: sum of 4 quarters · filed 2022-02-09 |
| 2021-06-30 | $0.00 10-Q · filed 2021-07-28 | $0.00 10-Q · filed 2021-07-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-09 | $0.00 derived: sum of 4 quarters · filed 2022-02-09 |
| 2021-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2022-02-09 | $0.00 derived: sum of 2 quarters · filed 2022-02-09 | $0.00 derived: sum of 3 quarters · filed 2022-02-09 | $21.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $0.00 derived: sum of 2 quarters · filed 2022-02-09 | $21.00M derived: sum of 3 quarters · filed 2022-02-09 | $21.00M 10-K · filed 2022-02-09 |
| 2020-09-30 | $0.00 10-Q · filed 2021-10-27 | $21.00M derived: sum of 2 quarters · filed 2021-10-27 | $21.00M 10-Q · filed 2021-10-27 | |
| 2020-06-30 | $21.00M 10-Q · filed 2021-07-28 | $21.00M 10-Q · filed 2021-07-28 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $0.00 derived: sum of 2 quarters · filed 2022-02-09 | $15.00M derived: sum of 3 quarters · filed 2022-02-09 | $15.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $15.00M derived: sum of 2 quarters · filed 2020-11-05 | $15.00M 10-Q · filed 2020-11-05 | $15.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $15.00M 10-Q · filed 2020-08-06 | $15.00M 10-Q · filed 2020-08-06 | $15.00M derived: sum of 3 quarters · filed 2021-02-10 | $15.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $0.00 10-Q · filed 2019-04-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-10 | $0.00 derived: sum of 3 quarters · filed 2021-02-10 | $0.00 derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $0.00 derived: sum of 2 quarters · filed 2021-02-10 | $0.00 derived: sum of 3 quarters · filed 2021-02-10 | $64.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | $64.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-07-25 | $64.00M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | $64.00M 10-Q · filed 2019-04-25 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-24 | |||
| 2017-06-30 | $0.00 10-Q · filed 2018-07-26 | $0.00 10-Q · filed 2018-07-26 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $0.00 derived: sum of 2 quarters · filed 2019-02-25 | $0.00 derived: sum of 3 quarters · filed 2019-02-25 | $15.00M 10-K · filed 2019-02-25 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $0.00 derived: sum of 2 quarters · filed 2017-10-26 | $15.00M 10-Q · filed 2017-10-26 | $15.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $15.00M 10-Q · filed 2017-07-27 | $15.00M derived: sum of 3 quarters · filed 2018-02-13 | $15.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $15.00M 10-Q · filed 2017-04-27 | $15.00M derived: sum of 2 quarters · filed 2018-02-13 | $15.00M derived: sum of 3 quarters · filed 2018-02-13 | $15.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $0.00 derived: sum of 2 quarters · filed 2018-02-13 | $0.00 derived: sum of 3 quarters · filed 2018-02-13 | $13.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $0.00 derived: sum of 2 quarters · filed 2016-10-27 | $13.00M 10-Q · filed 2016-10-27 | $24.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $13.00M 10-Q · filed 2016-07-28 | $24.00M derived: sum of 3 quarters · filed 2017-02-21 | $42.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $13.00M 10-Q · filed 2016-04-28 | $24.00M derived: sum of 2 quarters · filed 2017-02-21 | $42.00M derived: sum of 3 quarters · filed 2017-02-21 | |
| 2014-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $29.00M derived: sum of 2 quarters · filed 2017-02-21 | $29.00M 10-K · filed 2017-02-21 | |
| 2014-09-30 | $18.00M 10-Q · filed 2015-10-27 | $18.00M 10-Q · filed 2015-10-27 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $0.00 derived: sum of 2 quarters · filed 2015-02-13 | $0.00 derived: sum of 3 quarters · filed 2015-02-13 | $38.00M 10-K · filed 2015-02-13 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-23 | $0.00 derived: sum of 2 quarters · filed 2013-10-23 | $38.00M 10-Q · filed 2013-10-23 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $38.00M 10-Q · filed 2013-07-25 | ||
| 2012-03-31 | $38.00M 10-Q · filed 2013-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |